Questions About Cancer? 1-800-4-CANCER
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

News from NCI

  • A drug target that stimulates development of healthy stem cells
    NCI News Note

    (Posted: 04/17/2013) - Scientists have overcome a major impediment to the development of effective stem cell therapies by studying mice that lack CD47, a protein found on the surface of both healthy and cancer cells. They discovered that cells obtained from the lungs of CD47-deficient mice, but not from ordinary mice that have the CD47 gene, multiplied in a culture dish and spontaneously converted into stem cells

  • Testing lung cancer drugs and therapies in mice
    NCI News Note

    (Posted: 04/15/2013) - National Cancer Institute (NCI) investigators have designed a genetically engineered mouse for use in the study of human lung squamous cell carcinoma (SCC). SCC is a type of non-small cell lung carcinoma, one of the most common types of lung cancer, with a five-year survival rate of about 15 percent.

  • Two NCI investigators reviewing CT scan on computer screen with 26 year old male patient, shown at far right.  Cross-sectional scan on right side of screen shows 15 cm tumor mass in mediastinum and scan on left shows complete remission 7 months later with no tumor evident.
    NIH trial shows promising results in treating a lymphoma in young people
    NCI Press Release

    (Posted: 04/10/2013) - Patients with a type of cancer known as primary mediastinal B-cell lymphoma who received infusions of chemotherapy, but who did not have radiation therapy to an area of the thorax known as the mediastinum, had excellent outcomes, according to clinical trial results.

  • Schematic of TLR4-C/EBPdelta- FBXW7alpha feedback loops in inflammatory signaling, showing, with arrows, how these proteins interact with each other
    A tumor suppressor is identified as an inhibitor of inflammatory pathways
    NCI News Note

    (Posted: 04/09/2013) - Scientists at NCI have found that a protein, FBXW7, which acts as a tumor suppressor, is also important for the reduction in strength of inflammatory pathways. It has long been recognized that a complex interaction exists between cancer causing mechanisms and inflammation.

  • 3 investigators from NCI’s Pediatric Oncology Branch, standing side by side in the atrium of the D.C. convention center at the AACR 2013 annual meeting, with the AACR banner in the background. From left to right, Crystal Mackall, M.D., Daniel Lee, M.D., and Alan Wayne, M.D.
    Cancer immunotherapy in children: How does it differ from approaches in adults?
    NCI Perspective

    (Posted: 04/08/2013) - More often than not, cancer immunotherapies that work in adults are used in modified ways in children. Seldom are new therapies developed just for children, primarily because of the small number of pediatric patients relative to the adult cancer patient population. Depicted are members of NCI’s Pediatric Oncology Branch. From left: Drs. Crystal Mackall, Daniel Lee, and Alan Wayne

  • Mitochondrial chaperones may represent novel targets for developing anti-cancer drugs
    NCI News Note

    (Posted: 04/01/2013) - Scientists at NCI have found that a mitochondrial chaperone protein, TRAP1, may act indirectly as a tumor suppressor as well as a novel target for developing anti-cancer drugs. Chaperone proteins, such as TRAP1, help other proteins adapt to stress, but scientists are coming to appreciate that they have other functions as well, such as, in this case, affecting tumor development.

  • The potential of large studies for building genetic risk prediction models
    NCI News Note

    (Posted: 03/04/2013) - NCI scientists have developed a new paradigm to assess hereditary risk prediction in common diseases, such as prostate cancer. This genetic risk prediction concept is based on polygenic analysis—the study of a group of common DNA sequences, known as single nucleotide polymorphisms (SNPs), each of which contributes a very small amount to overall disease risk, but has a strong effect when grouped together.

  • NIH study finds increases in risk of certain leukemias related to treatment
    NCI Press Release

    (Posted: 02/14/2013) - A new study describes the pattern of risk for chemotherapy-related acute myeloid leukemia among adult cancer survivors over the past three decades who have previously been treated with chemotherapy for other cancers. These patterns coincide with major shifts in treatment practices. In particular, the study found that the risk of treatment-related AML among patients treated for non-Hodgkin lymphoma has increased steadily during the last few decades.

  • NCI study finds that sunitinib benefits patients with renal cell carcinoma
    NCI News Note

    (Posted: 02/07/2013) - Findings from clinical trial patients with metastatic renal cell carcinoma, a common kidney cancer, show they did not have accelerated tumor growth after treatment with sunitinib, in contrast to some study results in animals.

  •  Translucent plastic bag containing bevacizumab and other chemo drugs dripping through I.V. port
    Bevacizumab significantly improves survival for patients with recurrent and metastatic cervical cancer
    NCI Press Release

    (Posted: 02/07/2013, Updated: 06/02/2013) - Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the drug bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an analysis of a large, randomized clinical trial.

< Previous  1 2 3 4 5 6 7 8 9 10  Next >
  • Posted: August 13, 2012
  • Updated: August 13, 2012